Champions Oncology Inc (CSBR)
NASDAQHealth CareBiotechnologySnapshot 2026-11-05
$4.76-1.45%
Close 2026-11-05 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-05
QuarterlyIQ Insights · CSBR
How strong the business is — where it ranks within its sector on capital efficiency and cash generation, and how well management has been executing.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
A guidance track record builds as the company issues and delivers on guidance.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
Our focus remains on building sustainable growth across the business while continuing to improve profitability.”
Stated in 2 of 2 supplied quarters. Management reported: “First Quarter and Recent Highlights: • Revenue of $15.2 million, an increase of 8.8% year over year • Oncology services margin of 51%, compared with 43% in the prior-year period • Adjusted EBITDA of $671,000, compared with $59,000 in the prior-year period • Continued investment in the Company’s commercial organization, data platform and strategic growth initiatives Robert Brainin, CEO of Champions, commented, “We delivered strong performance in the first quarter of fiscal 2027, with improved study execution and conversion in our core research services business driving higher revenue and materially better margins.”
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 1 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated weak grew net income 29% of the time over the next year (vs 52% for the rest of the cohort, n=10118).
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
“Our focus remains on building sustainable growth across the business while continuing to improve profitability.””
“Fourth Quarter and Other Financial Highlights: • Record annual revenue of $59.4 million • Fourth quarter revenue of $13.8 million • Fourth quarter oncology services margin of 51% • Adjusted EBITDA of…”
“We are continuing to build on the foundation established last year, with a focus on driving revenue growth, maintaining expense discipline and converting that growth into improved profitability.”
Stated in 2 of 2 supplied quarters. Management reported: “First Quarter and Recent Highlights: • Revenue of $15.2 million, an increase of 8.8% year over year • Oncology services margin of 51%, compared with 43% in the prior-year period • Adjusted EBITDA of $671,000, compared with $59,000 in the prior-year period • Continued investment in the Company’s commercial organization, data platform and strategic growth initiatives Robert Brainin, CEO of Champions, commented, “We delivered strong performance in the first quarter of fiscal 2027, with improved study execution and conversion in our core research services business driving higher revenue and materially better margins.”
““We are continuing to build on the foundation established last year, with a focus on driving revenue growth, maintaining expense discipline and converting that growth into improved profitability.””
“We delivered record annual revenue despite the absence of the prior year's significant data licensing transaction and generated positive Adjusted EBITDA in each quarter of the fiscal year, reflecting…”
“At the same time, we continued to invest in our commercial organization, radiopharmaceutical capabilities, data platform and target discovery initiatives.
Stated in 2 of 2 supplied quarters. Management reported: ““At the same time, we continued to invest in our commercial organization, radiopharmaceutical capabilities, data platform and target discovery initiatives.” “Our core research services business performed well as we advanced several strategic initiatives, including expanding our radiopharmaceutical platform, strengthening our data strategy, making meaningful progress toward the commercial application of Corellia's technology, and growing our commercial organization.”
““At the same time, we continued to invest in our commercial organization, radiopharmaceutical capabilities, data platform and target discovery initiatives.”
“Our core research services business performed well as we advanced several strategic initiatives, including expanding our radiopharmaceutical platform, strengthening our data strategy, making meaningf…”
Control operating expenses and cost of oncology revenue to improve margins while supporting growth initiatives.
Invest in and grow the proprietary data platform to support long-term growth and commercial opportunities.
Over the trailing year it converted 1.68x of net income into operating cash flow.
Not enough signal yet.
Not enough signal to read sensitivity to the broad stock market, the US dollar, real (inflation-adjusted) rates, long-term interest rates, Fed net liquidity (low R² over the window).
2 material management or governance events in the past 24 months, led by executive changes. Historically, Health Care names rated stable grew net income 43% of the time over the next year (vs 45% for the rest of the cohort, n=9530).
Not investment advice. As of 2026-11-05.